Phase 2 study findings suggest obinutuzumab in combination with idelalisib is an effective treatment option for patients with relapsed/refractory WM.
True or False: In contrast to the first and second generation BTK inhibitors, the third‑generation LOXO‑305 is known to obtain non‑covalent binding and reversible qualities in patients with…
True or False: Results from a retrospective analysis suggest that both autologous and allogeneic stem cell transplantation have a potential role in the treatment of patients with Waldenström’s…
True or False: Ibrutinib does not promote long-term disease control in previously-treated Waldenstrom macroglobulinemia.
An analysis of a multi-center trial comprising patients with previously-treated WM has shown ibrutinib to have promising long-term activity in this setting.
True or False: Zanubrutinib has been associated with higher complete response and very good partial response rates in patients with WM.
True or False: The ASPEN trial was the first trial to compare BTK inhibitors head-to-head in any disease.
True or False: Ibrutinib may prevent lung injury and improve pulmonary function in hypoxic patients with WM who have COVID-19.
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.